Emapalumab in MAS secondary to stills disease 39 pts, median age 12, 2 pooled prospective, open label, single arm studies. Endpoint complete resolution at week 8-. Around 60% and partial resolution nearly 100% 67% had concomitant anakinra @RheumNow ##EULAR2026 #EULARBest https://t.co/sGm43C3LfH

Lung US for RA-ILD screening Comparison with diagnostic scores 147 RA pts (68 ILD on HRCT) Asymptomatic cohort Sens 95.4% Spe 77.7% Risk scores alone performed poorly. Combining US + risk scores boosted sensitivity to 100% → promising low-cost screening tool alongside HRCT. https://t.co/7C4zClaxry

Can AI read 20 years of RA X-rays? And how much faster/better than us? 20 years ESPOIR cohort 7500+ joints RADAR algorithm 94–95% accuracy compared with expert readers 99% spe 93% sens #OP0344 #EULAR2026 @RheumNow https://t.co/8hFHCY4SaY

Diet as a DMARD? The Evidence Is Still Hard to Swallow Dietary interventions are rarely taken as seriously as pharmacological therapies in rheumatology. Yet patients ask about them constantly, and an increasing number of studies suggest that nutrition may influence disease https://t.co/BLrr3CNZMg

Can AI spot RA inflammation from a thermal hand scan? Cohort 100 RA pts AI model analysing thermal images detected US PD+ wrist inflammation AUC 0.87 Main features wrist temperature & heat-pattern With all due validation could this be the next mass screening tool for RA? https://t.co/2AzXj5yQJI

No big surprise here, deucravacitinib does as well without MTX Pooled analysis of 52wk data of POETYK PSA Same ACR20/50/70 and MDA response profiles also similar safety profiles #POS0288 #EULAR2026 @RheumNow https://t.co/XqLfZstRuS

A biomarker for CV disease in RA? Anti-CXCR3 antibodies asso w/ atherosclerosis Confirmed in a validation cohort Adding Ab profile to the mSCORE increases AUC from 0.6 to 0.9 Sens from 30 to 69% How does it compare with other ways of detecting atherosclerosis? #POS0899 https://t.co/O7bsLrVyzo

How to treat #RA-#ILD Similar to #IPF Occurs older men esp Smoking risk Vaccines Etc Philippe Dieude #HOT #EULAR2026 @RheumNow https://t.co/F4h9daSLhF

Which b/tsDMARDs are effective in #axSpA? Stratified by extramusculoskeletal manifestations Check out the latest update of the treatment heatmap 🔥 By Astrid van Tubergen At axial and peripheral SpA at a crossroads session #EULAR2026 @RheumNow https://t.co/uTxEJqbDBm

Controversial #Rheumatoid #arthritis disease activity May not affect #ILD BUT affects #mortality level evidence +/- PHillippe Dieude said #Rx from RCTs #IS Ex #rituximab #antifibrotics #nintedanib #nerandomilast HOw to Treat RA-ILD June 5 #EULAR2026 @RheumNow @eular_ARD https://t.co/R60nX6XzL8

Which b/tsDMARDs are NOT effective in #axSpA? Check out the latest update of the treatment heatmap 🔥 By Astrid van Tubergen At axial and peripheral SpA at a crossroads session #EULAR2026 @RheumNow https://t.co/hqfLAYeri3